MAP2K7 and cancer: MEK inhibitors, such as Cobimetinib, Binimetinib, Selumetinib, and Trametinib, are targeted therapies that inhibit the MEK-ERK signaling pathway, which is often dysregulated in-cancer [19,20,21,22].